- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT04284774
Tipifarnib for behandling av avanserte solide svulster, lymfom eller histiocytiske lidelser med HRAS-genforandringer, en Pediatric MATCH Treatment Trial
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Fase 2-underprotokoll av Tipifarnib hos pasienter med svulster som har HRAS-genomiske endringer
This phase II pediatric MATCH trial studies how well tipifarnib works in treating patients with solid tumors that have recurred or spread to other places in the body (advanced), lymphoma, or histiocytic disorders, that have a genetic alteration in the gene HRAS. Tipifarnib may block the growth of cancer cells that have specific genetic changes in a gene called HRAS and may reduce tumor size.
Studieoversikt
Status
Forhold
- Ondartet fast neoplasma
- Tilbakevendende melanom
- Tilbakevendende ependymom
- Tilbakevendende Ewing-sarkom
- Tilbakevendende hepatoblastom
- Tilbakevendende Langerhans Cell Histiocytose
- Tilbakevendende ondartet kimcelletumor
- Tilbakevendende ondartet gliom
- Tilbakevendende medulloblastom
- Tilbakevendende nevroblastom
- Tilbakevendende non-Hodgkin lymfom
- Tilbakevendende osteosarkom
- Tilbakevendende perifer primitiv nevroektodermal svulst
- Tilbakevendende rhabdoid svulst
- Tilbakevendende rabdomyosarkom
- Tilbakevendende bløtvevssarkom
- Tilbakevendende WHO grad 2 gliom
- Ildfast ependymom
- Ildfast Ewing Sarkom
- Ildfast hepatoblastom
- Refraktær Langerhans Cell Histiocytose
- Refraktær ondartet kimcelletumor
- Ildfast malignt gliom
- Ildfast medulloblastom
- Ildfast nevroblastom
- Refraktært non-Hodgkin lymfom
- Ildfast osteosarkom
- Refraktær perifer primitiv nevroektodermal svulst
- Ildfast Rhabdoid Tumor
- Ildfast Rhabdomyosarkom
- Ildfast mykt vevssarkom
- Ildfast WHO Grade 2 Gliom
- Tilbakevendende skjoldbruskkjertelkarsinom
- Ildfast melanom
- Tilbakevendende binyrefeokromocytom
- Tilbakevendende ektomesenkymom
- Tilbakevendende nyre Wilms-svulst
- Tilbakevendende rhabdoide svulst i nyrene
- Refraktær binyre feokromocytom
- Refraktær rhabdoide svulst i nyrene
- Refraktært karsinom i skjoldbruskkjertelen
Intervensjon / Behandling
Detaljert beskrivelse
PRIMARY OBJECTIVE:
I. To determine the objective response rate (ORR; complete response + partial response) in pediatric patients treated with tipifarnib with advanced solid tumors (including central nervous system [CNS] tumors), lymphomas or histiocytic disorders that harbor activating genetic alterations in HRAS.
SECONDARY OBJECTIVES:
I. To estimate the progression free survival in pediatric patients treated with tipifarnib with advanced solid tumors (including CNS tumors), lymphomas or histiocytic disorders that harbor activating genetic alterations in HRAS.
II. To obtain information about the tolerability of tipifarnib in children and adolescents with relapsed or refractory cancer.
EXPLORATORY OBJECTIVES:
I. To evaluate other biomarkers as predictors of response to tipifarnib and specifically, whether tumors that harbor different missense mutations or variant allele frequency will demonstrate differential response to tipifarnib treatment.
II. To explore approaches to profiling changes in tumor genomics over time through evaluation of circulating tumor deoxyribonucleic acid (DNA).
OUTLINE:
Patients receive tipifarnib tablets 350 mg/m^2/dose orally (PO) or via nasogastric or gastric tube twice daily (BID) (maximum 600 mg/dose BID) with food on days 1-7 and 15-21. Treatment repeats every 28 days for up to 26 cycles (2 years) in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up at 30 days, then periodically thereafter.
Studietype
Registrering (Faktiske)
Fase
- Fase 2
Kontakter og plasseringer
Studiesteder
-
-
Alabama
-
Birmingham, Alabama, Forente stater, 35233
- Children's Hospital of Alabama
-
-
Alaska
-
Anchorage, Alaska, Forente stater, 99508
- Providence Alaska Medical Center
-
-
Arizona
-
Mesa, Arizona, Forente stater, 85202
- Banner Children's at Desert
-
Phoenix, Arizona, Forente stater, 85016
- Phoenix Childrens Hospital
-
Tucson, Arizona, Forente stater, 85719
- Banner University Medical Center - Tucson
-
-
Arkansas
-
Little Rock, Arkansas, Forente stater, 72202-3591
- Arkansas Children's Hospital
-
-
California
-
Downey, California, Forente stater, 90242
- Kaiser Permanente Downey Medical Center
-
Duarte, California, Forente stater, 91010
- City of Hope Comprehensive Cancer Center
-
Loma Linda, California, Forente stater, 92354
- Loma Linda University Medical Center
-
Long Beach, California, Forente stater, 90806
- Miller Children's and Women's Hospital Long Beach
-
Los Angeles, California, Forente stater, 90048
- Cedars-Sinai Medical Center
-
Los Angeles, California, Forente stater, 90027
- Children's Hospital Los Angeles
-
Los Angeles, California, Forente stater, 90095
- Mattel Children's Hospital UCLA
-
Madera, California, Forente stater, 93636
- Valley Children's Hospital
-
Oakland, California, Forente stater, 94609
- UCSF Benioff Children's Hospital Oakland
-
Oakland, California, Forente stater, 94611
- Kaiser Permanente-Oakland
-
Orange, California, Forente stater, 92868
- Children's Hospital of Orange County
-
Palo Alto, California, Forente stater, 94304
- Lucile Packard Children's Hospital Stanford University
-
Sacramento, California, Forente stater, 95817
- University of California Davis Comprehensive Cancer Center
-
San Diego, California, Forente stater, 92123
- Rady Children's Hospital - San Diego
-
San Diego, California, Forente stater, 92134
- Naval Medical Center -San Diego
-
San Francisco, California, Forente stater, 94158
- UCSF Medical Center-Mission Bay
-
Torrance, California, Forente stater, 90502
- Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
-
-
Colorado
-
Aurora, Colorado, Forente stater, 80045
- Children's Hospital Colorado
-
Denver, Colorado, Forente stater, 80218
- Rocky Mountain Hospital for Children-Presbyterian Saint Luke's Medical Center
-
-
Connecticut
-
Hartford, Connecticut, Forente stater, 06106
- Connecticut Children's Medical Center
-
New Haven, Connecticut, Forente stater, 06520
- Yale University
-
-
Delaware
-
Wilmington, Delaware, Forente stater, 19803
- Alfred I duPont Hospital for Children
-
-
District of Columbia
-
Washington D.C., District of Columbia, Forente stater, 20010
- Children's National Medical Center
-
Washington D.C., District of Columbia, Forente stater, 20007
- MedStar Georgetown University Hospital
-
-
Florida
-
Fort Lauderdale, Florida, Forente stater, 33316
- Broward Health Medical Center
-
Fort Myers, Florida, Forente stater, 33908
- Golisano Children's Hospital of Southwest Florida
-
Gainesville, Florida, Forente stater, 32610
- UF Health Cancer Institute - Gainesville
-
Hollywood, Florida, Forente stater, 33021
- Memorial Regional Hospital/Joe DiMaggio Children's Hospital
-
Jacksonville, Florida, Forente stater, 32207
- Nemours Children's Clinic-Jacksonville
-
Miami, Florida, Forente stater, 33155
- Nicklaus Children's Hospital
-
Miami, Florida, Forente stater, 33136
- University of Miami Miller School of Medicine-Sylvester Cancer Center
-
Miami, Florida, Forente stater, 33176
- Miami Cancer Institute
-
Orlando, Florida, Forente stater, 32827
- Nemours Children's Hospital
-
Orlando, Florida, Forente stater, 32803
- AdventHealth Orlando
-
Orlando, Florida, Forente stater, 32806
- Arnold Palmer Hospital for Children
-
Pensacola, Florida, Forente stater, 32504
- Sacred Heart Hospital
-
St. Petersburg, Florida, Forente stater, 33701
- Johns Hopkins All Children's Hospital
-
Tampa, Florida, Forente stater, 33606
- Tampa General Hospital
-
Tampa, Florida, Forente stater, 33607
- Saint Joseph's Hospital/Children's Hospital-Tampa
-
West Palm Beach, Florida, Forente stater, 33407
- Saint Mary's Medical Center
-
-
Georgia
-
Atlanta, Georgia, Forente stater, 30329
- Children's Healthcare of Atlanta - Arthur M Blank Hospital
-
Savannah, Georgia, Forente stater, 31404
- Memorial Health University Medical Center
-
-
Hawaii
-
Honolulu, Hawaii, Forente stater, 96826
- Kapiolani Medical Center for Women and Children
-
-
Idaho
-
Boise, Idaho, Forente stater, 83712
- Saint Luke's Cancer Institute - Boise
-
-
Illinois
-
Chicago, Illinois, Forente stater, 60637
- University of Chicago Comprehensive Cancer Center
-
Chicago, Illinois, Forente stater, 60612
- University of Illinois
-
Chicago, Illinois, Forente stater, 60611
- Lurie Children's Hospital-Chicago
-
Maywood, Illinois, Forente stater, 60153
- Loyola University Medical Center
-
Peoria, Illinois, Forente stater, 61637
- OSF Children's Hospital of Illinois
-
Springfield, Illinois, Forente stater, 62702
- Southern Illinois University School of Medicine
-
-
Indiana
-
Indianapolis, Indiana, Forente stater, 46202
- Riley Hospital for Children
-
Indianapolis, Indiana, Forente stater, 46260
- Ascension Saint Vincent Indianapolis Hospital
-
-
Iowa
-
Des Moines, Iowa, Forente stater, 50309
- Blank Children's Hospital
-
Iowa City, Iowa, Forente stater, 52242
- University of Iowa/Holden Comprehensive Cancer Center
-
-
Kentucky
-
Lexington, Kentucky, Forente stater, 40536
- University of Kentucky/Markey Cancer Center
-
Louisville, Kentucky, Forente stater, 40202
- Norton Children's Hospital
-
-
Louisiana
-
New Orleans, Louisiana, Forente stater, 70121
- Ochsner Medical Center Jefferson
-
New Orleans, Louisiana, Forente stater, 70118
- Children's Hospital New Orleans
-
-
Maine
-
Bangor, Maine, Forente stater, 04401
- Eastern Maine Medical Center
-
Scarborough, Maine, Forente stater, 04074
- Maine Children's Cancer Program
-
-
Maryland
-
Baltimore, Maryland, Forente stater, 21287
- Johns Hopkins University/Sidney Kimmel Cancer Center
-
Baltimore, Maryland, Forente stater, 21215
- Sinai Hospital of Baltimore
-
Baltimore, Maryland, Forente stater, 21201
- University of Maryland/Greenebaum Cancer Center
-
Bethesda, Maryland, Forente stater, 20892
- National Institutes of Health Clinical Center
-
-
Massachusetts
-
Boston, Massachusetts, Forente stater, 02215
- Dana-Farber Cancer Institute
-
Boston, Massachusetts, Forente stater, 02114
- Massachusetts General Hospital Cancer Center
-
Worcester, Massachusetts, Forente stater, 01655
- UMass Memorial Medical Center - University Campus
-
-
Michigan
-
Ann Arbor, Michigan, Forente stater, 48109
- C S Mott Children's Hospital
-
Detroit, Michigan, Forente stater, 48201
- Children's Hospital of Michigan
-
Detroit, Michigan, Forente stater, 48201
- Wayne State University/Karmanos Cancer Institute
-
East Lansing, Michigan, Forente stater, 48823
- Michigan State University
-
Grand Rapids, Michigan, Forente stater, 49503
- Corewell Health Grand Rapids Hospitals - Helen DeVos Children's Hospital
-
Kalamazoo, Michigan, Forente stater, 49007
- Bronson Methodist Hospital
-
Royal Oak, Michigan, Forente stater, 48073
- Corewell Health Children's
-
-
Minnesota
-
Minneapolis, Minnesota, Forente stater, 55404
- Children's Hospitals and Clinics of Minnesota - Minneapolis
-
Minneapolis, Minnesota, Forente stater, 55455
- University of Minnesota/Masonic Cancer Center
-
-
Mississippi
-
Jackson, Mississippi, Forente stater, 39216
- University of Mississippi Medical Center
-
-
Missouri
-
Kansas City, Missouri, Forente stater, 64108
- Children's Mercy Hospitals and Clinics
-
St Louis, Missouri, Forente stater, 63110
- Washington University School of Medicine
-
St Louis, Missouri, Forente stater, 63141
- Mercy Hospital Saint Louis
-
St Louis, Missouri, Forente stater, 63104
- Cardinal Glennon Children's Medical Center
-
-
Nebraska
-
Omaha, Nebraska, Forente stater, 68198
- University of Nebraska Medical Center
-
Omaha, Nebraska, Forente stater, 68114
- Children's Hospital and Medical Center of Omaha
-
-
Nevada
-
Las Vegas, Nevada, Forente stater, 89144
- Summerlin Hospital Medical Center
-
Las Vegas, Nevada, Forente stater, 89109
- Sunrise Hospital and Medical Center
-
Las Vegas, Nevada, Forente stater, 89135
- Alliance for Childhood Diseases/Cure 4 the Kids Foundation
-
Las Vegas, Nevada, Forente stater, 89102
- University Medical Center of Southern Nevada
-
Reno, Nevada, Forente stater, 89502
- Renown Regional Medical Center
-
-
New Hampshire
-
Lebanon, New Hampshire, Forente stater, 03756
- Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center
-
-
New Jersey
-
Hackensack, New Jersey, Forente stater, 07601
- Hackensack University Medical Center
-
Morristown, New Jersey, Forente stater, 07960
- Morristown Medical Center
-
New Brunswick, New Jersey, Forente stater, 08901
- Saint Peter's University Hospital
-
New Brunswick, New Jersey, Forente stater, 08903
- Rutgers Cancer Institute of New Jersey-Robert Wood Johnson University Hospital
-
-
New York
-
Albany, New York, Forente stater, 12208
- Albany Medical Center
-
Buffalo, New York, Forente stater, 14263
- Roswell Park Cancer Institute
-
Mineola, New York, Forente stater, 11501
- NYU Langone Hospital - Long Island
-
New Hyde Park, New York, Forente stater, 11040
- The Steven and Alexandra Cohen Children's Medical Center of New York
-
New York, New York, Forente stater, 10065
- Memorial Sloan Kettering Cancer Center
-
New York, New York, Forente stater, 10032
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center
-
New York, New York, Forente stater, 10065
- NYP/Weill Cornell Medical Center
-
New York, New York, Forente stater, 10016
- Laura and Isaac Perlmutter Cancer Center at NYU Langone
-
Rochester, New York, Forente stater, 14642
- University of Rochester
-
Stony Brook, New York, Forente stater, 11794
- Stony Brook University Medical Center
-
Syracuse, New York, Forente stater, 13210
- State University of New York Upstate Medical University
-
The Bronx, New York, Forente stater, 10467
- Montefiore Medical Center - Moses Campus
-
Valhalla, New York, Forente stater, 10595
- New York Medical College
-
-
North Carolina
-
Asheville, North Carolina, Forente stater, 28801
- Mission Hospital
-
Chapel Hill, North Carolina, Forente stater, 27599
- UNC Lineberger Comprehensive Cancer Center
-
Charlotte, North Carolina, Forente stater, 28203
- Carolinas Medical Center/Levine Cancer Institute
-
Charlotte, North Carolina, Forente stater, 28204
- Novant Health Presbyterian Medical Center
-
Durham, North Carolina, Forente stater, 27710
- Duke University Medical Center
-
Greenville, North Carolina, Forente stater, 27834
- East Carolina University
-
Winston-Salem, North Carolina, Forente stater, 27157
- Wake Forest University Health Sciences
-
-
North Dakota
-
Fargo, North Dakota, Forente stater, 58122
- Sanford Broadway Medical Center
-
-
Ohio
-
Akron, Ohio, Forente stater, 44308
- Children's Hospital Medical Center of Akron
-
Cincinnati, Ohio, Forente stater, 45229
- Cincinnati Children's Hospital Medical Center
-
Cleveland, Ohio, Forente stater, 44195
- Cleveland Clinic Foundation
-
Cleveland, Ohio, Forente stater, 44106
- Rainbow Babies and Childrens Hospital
-
Columbus, Ohio, Forente stater, 43205
- Nationwide Children's Hospital
-
Dayton, Ohio, Forente stater, 45404
- Dayton Children's Hospital
-
Toledo, Ohio, Forente stater, 43606
- ProMedica Toledo Hospital/Russell J Ebeid Children's Hospital
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Forente stater, 73104
- University of Oklahoma Health Sciences Center
-
-
Oregon
-
Portland, Oregon, Forente stater, 97239
- Oregon Health and Science University
-
Portland, Oregon, Forente stater, 97227
- Legacy Emanuel Children's Hospital
-
-
Pennsylvania
-
Allentown, Pennsylvania, Forente stater, 18103
- Lehigh Valley Hospital-Cedar Crest
-
Danville, Pennsylvania, Forente stater, 17822
- Geisinger Medical Center
-
Philadelphia, Pennsylvania, Forente stater, 19104
- Children's Hospital of Philadelphia
-
Philadelphia, Pennsylvania, Forente stater, 19134
- Saint Christopher's Hospital for Children
-
Pittsburgh, Pennsylvania, Forente stater, 15224
- Children's Hospital of Pittsburgh of UPMC
-
-
Rhode Island
-
Providence, Rhode Island, Forente stater, 02903
- Rhode Island Hospital
-
-
South Carolina
-
Columbia, South Carolina, Forente stater, 29203
- Prisma Health Richland Hospital
-
Greenville, South Carolina, Forente stater, 29605
- BI-LO Charities Children's Cancer Center
-
-
South Dakota
-
Sioux Falls, South Dakota, Forente stater, 57117-5134
- Sanford USD Medical Center - Sioux Falls
-
-
Tennessee
-
Chattanooga, Tennessee, Forente stater, 37403
- T C Thompson Children's Hospital
-
Knoxville, Tennessee, Forente stater, 37916
- East Tennessee Childrens Hospital
-
Memphis, Tennessee, Forente stater, 38105
- Saint Jude Children's Research Hospital
-
Nashville, Tennessee, Forente stater, 37232
- Vanderbilt University/Ingram Cancer Center
-
Nashville, Tennessee, Forente stater, 37203
- The Children's Hospital at TriStar Centennial
-
-
Texas
-
Austin, Texas, Forente stater, 78723
- Dell Children's Medical Center of Central Texas
-
Corpus Christi, Texas, Forente stater, 78411
- Driscoll Children's Hospital
-
Dallas, Texas, Forente stater, 75390
- UT Southwestern/Simmons Cancer Center-Dallas
-
Dallas, Texas, Forente stater, 75230
- Medical City Dallas Hospital
-
El Paso, Texas, Forente stater, 79905
- El Paso Children's Hospital
-
Fort Worth, Texas, Forente stater, 76104
- Cook Children's Medical Center
-
Houston, Texas, Forente stater, 77030
- UT MD Anderson Cancer Center
-
Houston, Texas, Forente stater, 77030
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center
-
Lubbock, Texas, Forente stater, 79410
- Covenant Children's Hospital
-
Lubbock, Texas, Forente stater, 79415
- UMC Cancer Center / UMC Health System
-
San Antonio, Texas, Forente stater, 78207
- Children's Hospital of San Antonio
-
San Antonio, Texas, Forente stater, 78229
- Methodist Children's Hospital of South Texas
-
Temple, Texas, Forente stater, 76508
- Scott and White Memorial Hospital
-
-
Utah
-
Salt Lake City, Utah, Forente stater, 84113
- Primary Children's Hospital
-
-
Vermont
-
Burlington, Vermont, Forente stater, 05405
- University of Vermont and State Agricultural College
-
-
Virginia
-
Falls Church, Virginia, Forente stater, 22042
- Inova Fairfax Hospital
-
Norfolk, Virginia, Forente stater, 23507
- Children's Hospital of The King's Daughters
-
Portsmouth, Virginia, Forente stater, 23708-2197
- Naval Medical Center - Portsmouth
-
Richmond, Virginia, Forente stater, 23298
- VCU Massey Comprehensive Cancer Center
-
-
Washington
-
Seattle, Washington, Forente stater, 98105
- Seattle Children's Hospital
-
Spokane, Washington, Forente stater, 99204
- Providence Sacred Heart Medical Center and Children's Hospital
-
Tacoma, Washington, Forente stater, 98405
- Mary Bridge Children's Hospital and Health Center
-
Tacoma, Washington, Forente stater, 98431
- Madigan Army Medical Center
-
-
West Virginia
-
Morgantown, West Virginia, Forente stater, 26506
- West Virginia University Healthcare
-
-
Wisconsin
-
Madison, Wisconsin, Forente stater, 53792
- University of Wisconsin Carbone Cancer Center - University Hospital
-
Marshfield, Wisconsin, Forente stater, 54449
- Marshfield Medical Center-Marshfield
-
Milwaukee, Wisconsin, Forente stater, 53226
- Children's Hospital of Wisconsin
-
-
-
-
-
San Juan, Puerto Rico, 00926
- University Pediatric Hospital
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
-
Patient must have enrolled onto APEC1621SC (NCT03155620) and must have been given a treatment assignment to MATCH to APEC1621M based on the presence of an actionable mutation as defined in APEC1621SC
-
Patients must be >=12 months and =< 21 years of age at the time of study enrollment
-
Patients must have a body surface area >= 0.29 m^2 at enrollment
-
Patients must have radiographically measurable disease at the time of study enrollment. Patients with neuroblastoma who do not have measurable disease but have metaiodobenzylguanidine (MIBG) positive (+) evaluable disease are eligible. Measurable disease in patients with CNS involvement is defined as any lesion that is at minimum 10 mm in one dimension on standard magnetic resonance imaging (MRI) or computed tomography (CT)
-
Note: The following do not qualify as measurable disease:
- Malignant fluid collections (e.g., ascites, pleural effusions)
- Bone marrow infiltration except that detected by MIBG scan for neuroblastoma
- Lesions only detected by nuclear medicine studies (e.g., bone, gallium or positron emission tomography [PET] scans) except as noted for neuroblastoma
- Elevated tumor markers in plasma or cerebral spinal fluid (CSF)
- Previously radiated lesions that have not demonstrated clear progression post radiation
- Leptomeningeal lesions that do not meet the measurement requirements for Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
-
-
Karnofsky >= 50 for patients > 16 years of age and Lansky >= 50 for patients =< 16 years of age. Note: Neurologic deficits in patients with CNS tumors must have been relatively stable for at least 7 days prior to study enrollment. Patients who are unable to walk because of paralysis, but who are up in a wheelchair, will be considered ambulatory for the purpose of assessing the performance score
-
Patients must have fully recovered from the acute toxic effects of all prior anti-cancer therapy and must meet the following minimum duration from prior anti-cancer directed therapy prior to enrollment. If after the required timeframe, the numerical eligibility criteria are met, e.g. blood count criteria, the patient is considered to have recovered adequately
-
Cytotoxic chemotherapy or other anti-cancer agents known to be myelosuppressive
- >= 21 days after the last dose of cytotoxic or myelosuppressive chemotherapy (42 days if prior nitrosourea)
-
Anti-cancer agents not known to be myelosuppressive (e.g. not associated with reduced platelet or absolute neutrophil count [ANC] counts): >= 7 days after the last dose of agent
-
Antibodies: >= 21 days must have elapsed from infusion of last dose of antibody, and toxicity related to prior antibody therapy must be recovered to grade =< 1
-
Corticosteroids: If used to modify immune adverse events related to prior therapy, >= 14 days must have elapsed since last dose of corticosteroid
-
Hematopoietic growth factors: >= 14 days after the last dose of a long-acting growth factor (e.g. pegfilgrastim) or 7 days for short-acting growth factor. For growth factors that have known adverse events occurring beyond 7 days after administration, this period must be extended beyond the time during which adverse events are known to occur. The duration of this interval must be discussed with the study chair and the study-assigned research coordinator
-
Interleukins, interferons and cytokines (other than hematopoietic growth factors): >= 21 days after the completion of interleukins, interferon or cytokines (other than hematopoietic growth factors)
-
Stem cell infusions (with or without total body irradiation [TBI]):
- Allogeneic (non-autologous) bone marrow or stem cell transplant, or any stem cell infusion including donor lymphocyte infusion (DLI) or boost infusion: >= 84 days after infusion and no evidence of graft versus host disease (GVHD)
- Autologous stem cell infusion including boost infusion: >= 42 days
-
Cellular therapy: >= 42 days after the completion of any type of cellular therapy (e.g. modified T cells, natural killer [NK] cells, dendritic cells, etc.)
-
Radiation therapy (XRT)/external beam irradiation including protons: >= 14 days after local XRT; >= 150 days after TBI, craniospinal XRT or if radiation to >= 50% of the pelvis; >= 42 days if other substantial bone marrow (BM) radiation
- Note: Radiation may not be delivered to "measurable disease" tumor site(s) being used to follow response to subprotocol treatment
-
Radiopharmaceutical therapy (e.g., radiolabeled antibody, 131I-MIBG): >= 42 days after systemically administered radio-pharmaceutical therapy
-
Patients must not have received prior exposure to tipifarnib
-
-
For patients with solid tumors without known bone marrow involvement (within 7 days prior to enrollment):
- Peripheral absolute neutrophil count (ANC) >= 1000/mm^3
-
For patients with solid tumors without known bone marrow involvement (within 7 days prior to enrollment):
- Platelet count >= 100,000/mm^3 (transfusion independent, defined as not receiving platelet transfusions for at least 7 days prior to enrollment)
-
Patients with known bone marrow metastatic disease will be eligible for study provided they meet the blood counts (may receive transfusions provided they are not known to be refractory to red cell or platelet transfusions). These patients will not be evaluable for hematologic toxicity
-
Creatinine clearance or radioisotope glomerular filtration rate (GFR) >= 70 ml/min/1.73 m^2 (within 7 days prior to enrollment) or
-
A serum creatinine based on age/gender as follows (within 7 days prior to enrollment):
-
Age: Maximum serum creatinine (mg/dL)
- 1 to < 2 years: male (0.6), female (0.6)
- 2 to < 6 years: male (0.8), female (0.8)
- 6 to < 10 years: male (1), female (1)
- 10 to < 13 years: male (1.2), female (1.2)
- 13 to < 16 years: male (1.5), female (1.4)
- >= 16 years: male (1.7), female (1.4)
-
-
Bilirubin (sum of conjugated + unconjugated) =< 1.5 x upper limit of normal (ULN) for age (within 7 days prior to enrollment)
-
Serum glutamate pyruvate transaminase (SGPT) (alanine aminotransferase [ALT]) =< 135 U/L. (For the purpose of this study, the ULN for SGPT is 45 U/L.) (within 7 days prior to enrollment)
-
Serum albumin >= 2 g/dL (within 7 days prior to enrollment)
-
Patients with seizure disorder may be enrolled if on anticonvulsants and well controlled
-
Nervous system disorders (Common Terminology Criteria for Adverse Events [CTCAE] version [v] 5.0) resulting from prior therapy must be =< grade 2
-
Patients must be able to swallow intact tablets or crushed tablets mixed in water, orange juice, apple juice, tomato juice, ginger ale, applesauce, yogurt, protein shake, or a dietary supplement drink (such as Ensure). Percutaneous endoscopic gastrostomy (PEG)-tube or nasogastric tube administration is permitted
-
All patients and/or their parents or legally authorized representatives must sign a written informed consent. Assent, when appropriate, will be obtained according to institutional guidelines
Exclusion Criteria:
- Pregnant or breast-feeding women will not be entered on this study due to risks of fetal and teratogenic adverse events as seen in animal/human studies. Pregnancy tests must be obtained in girls who are post-menarchal. Males or females of reproductive potential may not participate unless they have agreed to use two effective contraceptive methods for the duration of study treatment. Both female subjects and male subjects with female partners of child-bearing potential must agree to use a highly effective method of contraception for 2 weeks prior to protocol therapy, during, and at least 4 weeks after last dose of tipifarnib. In addition, since tipifarnib could induce toxicity of male reproductive organs and cause impairment of fertility, sperm cryopreservation should be recommended for male subjects wishing to preserve their fertility following tipifarnib treatment
- Patients receiving corticosteroids who have not been on a stable or decreasing dose of corticosteroid for at least 7 days prior to enrollment are not eligible. If used to modify immune adverse events related to prior therapy, >= 14 days must have elapsed since last dose of corticosteroid
- Patients who are currently receiving another investigational drug are not eligible
- Patients who are currently receiving other anti-cancer agents are not eligible
- Patients who are receiving cyclosporine, tacrolimus or other agents to prevent graft-versus-host disease post bone marrow transplant are not eligible for this trial
- Patients who are currently receiving drugs that are strong inducers or inhibitors of CYP3A4/5 or UGT are not eligible. Strong inducers or inhibitors of CYP3A4/5 or UGT should be avoided from 14 days prior to the 1st dose of tipifarnib to the end of the study. In addition, patients receiving agents that are sensitive or narrow therapeutic range substrates of CYP3A4/5 are not eligible. Note: CYP3A4/5 inducing anti-epileptic drugs and dexamethasone for CNS tumors or metastases, on a stable dose, are allowed
- Patients with known hypersensitivity to tipifarnib or any components of the tablet are not eligible
- Patients with hypersensitivity to imidazoles, such as clotrimazole, ketoconazole, miconazole and others in this drug class are not eligible
- Patients who have an uncontrolled infection are not eligible
- Patients who have received a prior solid organ transplantation are not eligible
- Patients who in the opinion of the investigator may not be able to comply with the safety monitoring requirements of the study are not eligible
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: N/A
- Intervensjonsmodell: Enkeltgruppeoppdrag
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: Treatment (tipifarnib)
Patients receive tipifarnib tablets 350 mg/m^2/dose PO or via nasogastric or gastric tube BID (maximum 600 mg/dose BID) with food on days 1-7 and 15-21. Treatment repeats every 28 days for up to 26 cycles (2 years) in the absence of disease progression or unacceptable toxicity. |
Tipifarnib tablets
Andre navn:
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Objective Response Rate (Complete Response + Partial Response) in Pediatric Patients Treated With Tipifarnib
Tidsramme: Up to 2 years from study entry
|
A responder is defined as a patient who achieves a best response of partial response or complete response on the study. Response rates will be calculated as the percent of evaluable patients who are responders, and confidence intervals will be constructed using the Wilson score interval method. The revised Response Evaluation Criteria in Solid Tumors (RECIST) guideline (version 1.1) was used to determine response and progression in this study, with specific criteria outlined for the different subtypes of tumors (e.g., 2-dimensional measurements for central nervous system (CNS) tumors. |
Up to 2 years from study entry
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Percentage of Patients Experiencing Grade 3 or Higher Adverse Events
Tidsramme: Up to 2 years from study entry
|
Percentage of patients experiencing grade 3 or higher adverse events will be evaluated according to National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0 |
Up to 2 years from study entry
|
|
Progression Free Survival (PFS)
Tidsramme: Up to 6 months from study entry
|
The Kaplan-Meier method will be used to estimate the 6-month PFS. PFS is defined as time from initiation of protocol treatment to disease progression, recurrence, death from any cause, or date of last contact |
Up to 6 months from study entry
|
Andre resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Biomarker Analysis
Tidsramme: Up to 7 years
|
Will evaluate other biomarkers as predictors of response to tipifarnib and whether tumors that harbor different missense mutations or fusions will demonstrate differential response to treatment. |
Up to 7 years
|
|
Profiling Changes in Tumor Genomics
Tidsramme: Baseline, prior to cycle 5, end of treatment, assessed up to 7 years
|
Will explore approaches to the profiling changes in tumor genomics over time through evaluation of circulating tumor deoxyribonucleic acid. |
Baseline, prior to cycle 5, end of treatment, assessed up to 7 years
|
Samarbeidspartnere og etterforskere
Sponsor
Etterforskere
- Hovedetterforsker: Christine A Pratilas, Children's Oncology Group
Publikasjoner og nyttige lenker
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Faktiske)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
- Urogenitale sykdommer
- Sykdommer i det endokrine systemet
- Urogenitale neoplasmer
- Neoplasmer etter nettsted
- Neoplasmer
- Mannlige urogenitale sykdommer
- Nyresykdommer
- Urologiske sykdommer
- Kvinnelige urogenitale sykdommer
- Kvinnelige urogenitale sykdommer og graviditetskomplikasjoner
- Genetiske sykdommer, medfødte
- Sykdommer i immunsystemet
- Sykdommer i luftveiene
- Neoplasmer etter histologisk type
- Lungesykdommer
- Neoplasmer i endokrine kjertel
- Neoplasmer i hode og nakke
- Neoplasmer, kjertel og epitel
- Hudsykdommer
- Lymfesykdommer
- Lymfoproliferative lidelser
- Immunproliferative lidelser
- Urologiske neoplasmer
- Neoplasmer, Neuroepithelial
- Nevroektodermale svulster
- Neoplasmer, kjønnsceller og embryonale
- Neoplasmer, nervevev
- Lymfom
- Lungesykdommer, interstitielle
- Nyre-neoplasmer
- Neoplastiske syndromer, arvelig
- Paragangliom
- Nevroendokrine svulster
- Neoplasmer, bindevev og mykt vev
- Neuroektodermale svulster, primitive
- Neoplasmer, beinvev
- Neoplasmer, bindevev
- Nevi og melanomer
- Neoplasmer i huden
- Neoplasmer, muskelvev
- Neoplasmer, komplekse og blandede
- Myosarkom
- Skjoldbrusk sykdommer
- Histiocytose
- Medfødte, arvelige og neonatale sykdommer og abnormiteter
- Hud- og bindevevssykdommer
- Hemic og lymfatiske sykdommer
- Glioma
- Feokromocytom
- Nevroblastom
- Sarkom, Ewing
- Lymfom, Non-Hodgkin
- Melanom
- Sarkom
- Rhabdomyosarkom
- Neuroektodermale svulster, primitive, perifere
- Osteosarkom
- Ependymom
- Medulloblastom
- Wilms Tumor
- Rabdoide svulst
- Hepatoblastom
- Histiocytose, Langerhans-celle
- Neoplasmer i skjoldbruskkjertelen
- tipifarnib
Andre studie-ID-numre
- NCI-2020-01015
- U10CA180886 (U.S. NIH-stipend/kontrakt)
- NCI-2020-01015 (Registeridentifikator: CTRP (Clinical Trial Reporting Program))
- APEC1621M (Annen identifikator: CTEP)
- APEC1621M (Annen identifikator: Children's Oncology Group)
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
IPD-planbeskrivelse
NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page.
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .